Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Deudomperidone
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 27, 2025
Lead Product(s) : Deudomperidone
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CIN-110
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
CinFina Pharma Begins Phase 1 MAD Trial of CIN-110 for Obesity
Details : CIN-110 is a potent and highly selective large molecule peptide and a PYY3-36 analog, which is currently under development for the treatment of Obesity.
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
July 30, 2024
Lead Product(s) : CIN-110
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CIN-109
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : $176.0 million
Deal Type : Financing
CinRx Pharma Announces Additional $73 Million Financing
Details : The financing aims to support the CinRx to focus on the clinical development of CIN-109, which is being evaluated in the early-stage clinical trial studies to treat obesity.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 30, 2024
Lead Product(s) : CIN-109
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : $176.0 million
Deal Type : Financing
Lead Product(s) : Deudomperidone
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : CinRx Pharma
Deal Size : $59.0 million
Deal Type : Series B Financing
CinDome Pharma Announces $40 Million Series B Extension
Details : The financing aims to support the continued development of CIN-102 (deudomperidone) for the treatment of chronic gastroparesis, including preparation for registrational trials.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 16, 2024
Lead Product(s) : Deudomperidone
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : CinRx Pharma
Deal Size : $59.0 million
Deal Type : Series B Financing
Lead Product(s) : CIN-110
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
CinFina Announces FDA Clearance and First Doses in Phase 1 Trial of CIN-110
Details : CIN-110 is a potent and highly selective large molecule peptide and a PYY3-36 analog, which is currently under development for the treatment of Obesity.
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
March 26, 2024
Lead Product(s) : CIN-110
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Deudomperidone
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 27, 2023
Lead Product(s) : Deudomperidone
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Deudomperidone
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CIN-102 (deudomperidone) is a new chemical entity based upon deuteration and novel formulation of domperidone (DA2-receptor antagonist), a frequently prescribed first line therapy for nausea, vomiting, and gastroparesis outside of the United States.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 27, 2023
Lead Product(s) : Deudomperidone
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Deudomperidone
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : CinRx Pharma
Deal Size : $19.0 million
Deal Type : Private Placement
Details : The net proceeds will be used to develop CinDome Pharma’s Phase 2 envision3D study of CIN-102 (deudomperidone), a new chemical entity based upon deuteration and novel formulation of domperidone in patients with diabetic gastroparesis.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 27, 2023
Lead Product(s) : Deudomperidone
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : CinRx Pharma
Deal Size : $19.0 million
Deal Type : Private Placement
Lead Product(s) : Cadisegliatin
Therapeutic Area : Endocrinology
Study Phase : Phase I/ Phase II
Recipient : vTv Therapeutics
Deal Size : $10.0 million
Deal Type : Agreement
vTv Therapeutics Announces Investment by CinRx Pharma
Details : In addition to the investment, the agreements set forth the terms under which vTv will leverage the CinRx team’s industry experience to collaborate on the oversight of the clinical trials for pharmaceutical products that contain TTP399.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : $6.0 million
July 25, 2022
Lead Product(s) : Cadisegliatin
Therapeutic Area : Endocrinology
Highest Development Status : Phase I/ Phase II
Recipient : vTv Therapeutics
Deal Size : $10.0 million
Deal Type : Agreement
Lead Product(s) : CIN-109
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase I
Sponsor : Janssen Ireland
Deal Size : Undisclosed
Deal Type : Licensing Agreement
CinFina Pharma In-Licenses Obesity Portfolio
Details : Under the agreement CinFina will be responsible for development, manufacturing and commercialization of CIN-109, with a multiple ascending dose Phase 1 clinical study, and following dose selection, will commence a Phase 2 study in overweight and obese ad...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
September 22, 2021
Lead Product(s) : CIN-109
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I
Sponsor : Janssen Ireland
Deal Size : Undisclosed
Deal Type : Licensing Agreement